PCSK9 Drugs Emerging as Strong Cholesterol-Lowering Agents

Recent research touts the effectiveness of PCSK9 inhibitors, but their price may remain an obstacle for many people.

Since the cholesterol-lowering drugs PCSK9 inhibitors were first approved by the U.S. Food and Drug Administration (FDA) two years ago, there has been considerable curiosity about just how effective they can be, and whether they will be affordable for the averageconsumer.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Heart Advisor

Get the next year of Heart Advisor for just $20. And access all of our online content - over 2,000 articles - free of charge.
Subscribe today and save 38%. It's like getting 5 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access